Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing a paradigm of drug innovation: an evaluation algorithm.

Luciano Caprino1, Pierluigi Russo

  • 1Department of Human Physiology and Pharmacology, University La Sapienza, Rome, 00185, Italy. luciano.caprino@uniroma1.it

Drug Discovery Today
|October 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Schubert et al. Minimally Invasive Ablation Strategies for Renal Cell Carcinoma Patients Ineligible for Surgery. <i>Life</i> 2026, <i>16</i>, 73.

Life (Basel, Switzerland)·2026
Same author

Male Urinary Incontinence Severity and Non-Adjustable Sling Outcomes: Protocol for a Multivariate Dose-Response Meta-Analysis.

Journal of clinical medicine·2026
Same author

Early Postoperative Outcomes with the Toumai<sup>®</sup> Surgical System for Robot-Assisted Radical Prostatectomy: A Prospective Comparative Study with da Vinci<sup>®</sup>.

Cancers·2026
Same author

Lifestyle Interventions in Patients in Active Surveillance for Prostate Cancer: A Systematic Review.

Journal of clinical medicine·2026
Same author

Retroperitoneal robotic partial nephrectomy with the Versius system: a case series.

Minerva urology and nephrology·2026
Same author

Partial versus radical nephrectomy for pT3a renal cell carcinoma: a systematic review and meta-analysis.

Journal of robotic surgery·2026

This study introduces the innovation assessment algorithm (IAA), a new model to evaluate drug innovation. IAA scores new medicines by analyzing data from pre- and post-marketing phases.

Area of Science:

  • Pharmacoeconomics
  • Health Services Research
  • Drug Development

Background:

  • Assessing drug innovation is complex, involving multiple stakeholder perspectives (patients, policymakers, regulators, industry).
  • A new medicine's innovative value is influenced by its intrinsic properties and external factors like market context and existing treatments.
  • Existing assessment methods may not fully capture the dynamic nature of a drug's innovative value over time.

Purpose of the Study:

  • To introduce and describe the Innovation Assessment Algorithm (IAA), a simulation model for evaluating drug innovation.
  • To develop a model capable of assessing both intrinsic compound properties and context-dependent changes in innovative value.
  • To provide a quantitative score for drug innovation based on comprehensive data analysis.

Main Methods:

Related Experiment Videos

  • Development of the Innovation Assessment Algorithm (IAA), a simulation-based model.
  • Integration of data from both the pre-marketing (R&D) and post-marketing authorization phases.
  • Assessment of intrinsic compound properties and modifications in innovative value over time.

Main Results:

  • The IAA model provides a quantifiable score for drug innovation.
  • The algorithm analyzes information generated throughout the drug development lifecycle.
  • The model accounts for the dynamic nature of a drug's innovative value.

Conclusions:

  • The Innovation Assessment Algorithm (IAA) offers a novel approach to drug innovation assessment.
  • IAA integrates pre- and post-marketing data for a holistic evaluation.
  • This model aids in understanding the evolving innovative value of medicines.